Achieving Optimal Outcomes for Patients with Rheumatoid Arthritis and Comorbid Conditions: A Team Approach

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: May 17, 2016
  • Expires: May 16, 2017
  • Average User Rating:
    ( Ratings)

 

 

Faculty

 This activity has 4 faculty members associated with it.
Click Here to View All
Naomi Amudala Naomi Amudala, RN, FNP-BC
Clinical Instructor and Nurse Practitioner
Vasculitis Center/Rheumatology
Boston University School of Medicine
Boston, MA

Mark  C.  Fisher Mark C. Fisher, MD, MPH
Assistant Clinical Director
Department of Rheumatology
Massachusetts General Hospital
Boston, MA

Jon  T.  Giles Jon T. Giles, MD, MPH
Assistant Professor of Medicine
Division of Rheumatology
Columbia University, College of Physicians and Surgeons
New York Presbyterian Hospital
New York, NY

Tuhina Neogi Tuhina Neogi, MD
Associate Professor of Medicine
Boston University School of Medicine
Associate Professor of Epidemiology
Boston University School of Public Health
Boston, MA

Needs Statement

Current literature indicates that rheumatologists are not providing optimal care when managing patients with RA.  Practice gaps include: 1) variation in treatment; 2) lack of knowledge regarding safety issues and biologic treatment; 3); 4) lack of knowledge and competence determining whether and when monotherapy or combination therapeutic treatment is suitable; 5) challenges in identifying the benefits and safety risks of available therapies including drug interactions

Target Audience

Rheumatologists Nurse Practitioners, Nurses, Physician Assistants, other healthcare providers who treat patients with RA

Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Articulate increased confidence in the identification of RA in patients with comorbid conditions
  2. Recognize whichpatients with RA and comorbid conditions are candidates for use of biological therapies
  3. Identify strategies to use in practice for providing interdisciplinary management of RA and comorbidities
  4. List the benefits and the safety risks of available and pending therapies for RA treatment  for patients with comorbid conditions
  5. Demonstrate increased competence in the ability to monitor patients with RA and comorbid conditions 

Faculty Disclosure

Boston University School of Medicine asks all individuals involved in the development of Continuing Medical Education (CME) activities to disclose relevant relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty:
Dr. Neogi has no relevant financial relationships with commercial interest
Dr. Giles support from Genentech. He is a consultant for Pfizer and he sits on the board for Coherus.
Dr. Fisher has no relevant relationships with commercial interests.
Ms. Amudala has no relevant financial relationships with commercial interest.

Planning Committee Disclosure
Patti-Ann Collins, DNP, MSN/MBA, RN, Lead Nurse Planner, has no relevant financial relationships with any commercial interest.
Elizabeth Drury, planner, hasno relevant financial relationships with any commercial interest.
Jody Walker, MS, planner, has no relevant financial relationships with any commercial interest.
Julie White, MS, planner, has no relevant financial relationships with any commercial interest.
Josh Kilbridge, medical writer,has no relevant financial relationships with any commercial interest

COMMERCIAL SUPPORT
This activity is supported by an unrestricted educational grant from Pfizer.